This was issued specifically re: Prolia, with no mention of Xgeva. However patients should be alerted, and of course don't change your medications without first speaking to your doctor about this.
FDA alert re: denosumab: This was... - Advanced Prostate...
FDA alert re: denosumab
Written by
dentaltwin
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
No worries. Should be monitoring calcium regularly anyway. Those with severe renal function impairment need to be especially careful.
Not what you're looking for?
You may also like...
Lu177PSMA617 (Pluvicto) FDA-approved today
It was approved only for for patients who are metastatic and have been previously treated with...
QoL Alert!!! Super QoL ifragilisticexpialidocious
Had a QoLy Holiday with Mary(Poppins) the Musical in Redondo Beach with a former front desk lady...
How long before FDA approves Nubeqa for doublet?
The FDA has accepted a supplemental new drug application (sNDA) seeking the approval of...
Question re Lu177 failure
When patients fail Lu177 treatment, are any of the remaining cancer cells Psma positive, or have...
should APCa patients wear medical alert bracelets
My thoughts, not sure -- are there emergency meds/procedures that would need to know APCa...
Re-treatment with radium-223.
Denosumab, is it worth it
CCW702 - FDA clears its IND for new immunotherapeutic for treating prostate cancer Aug 21 2019
Article: FDA grants 177Lu-PSMA-617 breakthrough designation for mCRPC
Question for men on Denosumab (Xgeva)
